作者
Kexiang Yan,Fuqiu Li,Xiaodong Bi,Ling Han,Zhenghua Zhang,Rixin Chen,Yu‐Ye Li,Litao Zhang,Xiao Hua Wang,Linfeng Li,Jianyun Lu,Aie Xu,Sen Yang,Yan Lü,Jianfang Sun,Zhiming Li,Xiaohong Zhu,Jiang Mei-ying,Siping Zhang,Wenqin Wang,Yanlin Li,Zudong Meng,Hongyi Li,Kuanhou Mou,Xiuping Han,Shanshan Li,Aijun Chen,Xin Li,Donghua Liu,Chunlei Zhang,Chao Ji,Jing Wang,Hao Cheng,Xiaojing Cui,Xiaoyan Yao,Xiaoyan Bai,Guangchao Dong,Jinhua Xu
摘要
Vunakizumab, a novel anti-IL-17A antibody, has showed promising efficacy for moderate-to-severe plaque psoriasis in a phase 2 trial.